Oc­u­lar cuts staff in wake of FDA slap­down; Bio­gen re­cruits Pfiz­er vet; X4 inks dis­cov­ery deal with Yale

→ Just days af­ter its bid to sal­vage its sec­ond ap­pli­ca­tion for the drug/de­vice eye ther­a­py Dex­ten­za failed with an­oth­er slap­down by reg­u­la­tors, the Oc­u­lar Ther­a­peu­tics $OCUL is cut­ting staff and shak­ing up the C suite. The biotech said that Antony Mat­tes­sich has as­sumed the role of CEO while for­mer CEO Amar Sawh­ney has tran­si­tioned to ex­ec­u­tive chair­man. The biotech al­so re­duced its head count by 19%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER